ArticleInfluenza and other respiratory viruses2025
Molecular Evolution of Influenza A Viruses From Mauritius, 2017-2019.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDespite being a vaccine preventable disease, influenza remains a burden in African countries. In Mauritius, influenza virus activity is year-round but evidence-based data to guide vaccination and pandemic preparedness strategies are lacking. This study aimed to describe the genetic diversity of influenza A viruses detected in Mauritius between 2017 and 2019.
methodsInfluenza A/H1N1pdm09 and A/H3N2 virus isolates were sequenced using Oxford Nanopore technology. Sequence reads assembled by CZ ID and Genome Detective web-based tools were uploaded to the EpiFlu database of the Global Initiative on Sharing All Influenza Data (GISAID). Sequence alignments and phylogenetic analysis were performed using Nextclade and MEGA XI software. BioEdit software was used to view amino acid substitutions compared to annual vaccine strains. Prediction of potential N-linked glycosylation (PNG) sites was determined by NetNGlyc 1.0.
resultsInfluenza A was predominant (92.6%), with A/H1N1pdm09 prevailing overall (62.5%) but A/H3N2 dominating in 2017 (55.9%). Phylogenetic analysis identified clade 6B dominance for A/H1N1pdm09, with notable substitutions E119K, Q136K and D151E linked to antigenic changes. A/H3N2 exhibited significant genetic diversity, with co-circulation of 3C.2a4 and 3C.2a1 in 2017 while 2018 predominant subclade 3C.2a1b.1 highlights continued antigenic drift. Loss of PNG sites at position 158 (11/21; 52.4%) in HA and position 329 (81.0%, 17/21) in NA of A/H3N2 viruses were observed.
conclusionsContinued evolution of A/H1N1pdm09 and A/H3N2 viruses in Mauritius highlights the need for sustained genomic surveillance to inform vaccine and antiviral strategies. Data from Mauritius will contribute to understanding of influenza viruses' ecology in the African region and globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.